Clinical Trials Logo
  1. Home
  2. Homocystinuria
  3. NCT05462132

Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult Volunteers — HCU  

Homocystinuria Clinical Trial

Official title:
A Phase 1, Dose-escalation, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacodynamics of SYNB1353 in Healthy Volunteers

Clinical Trial Summary

This is a Phase 1, double-blind (Sponsor-open), placebo-controlled, randomized, dose-escalation, inpatient study using a multiple-ascending dose (MAD) design to assess the safety, tolerability, and PD of SYNB1353 in HVs.

Clinical Trial Description

This study is evaluating the safety, tolerability and PD of SYNB1353 in up to 8 cohorts of HVs. In each cohort, HVs will be randomly assigned to investigational medicinal product (IMP), according to a MAD design, to receive either SYNB1353 or placebo (6 active:2 placebo per cohort). A methionine loading study will be performed on Day -1 and Day 7. At each IMP dose level, a dose of methionine will be evaluated. The methionine dose may increase if necessary to evaluate the PD of SYNB1353. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05462132
Study type Interventional
Source Synlogic
Contact
Status Completed
Phase Phase 1
Start date July 7, 2022
Completion date November 27, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Recruiting NCT05910151 - Selective Screening of Children for Hereditary Metabolic Diseases by Tandem Mass Spectrometry in Kazakhstan
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Completed NCT00483314 - Homocystinuria: Treatment With N-Acetylcysteine Phase 2
Recruiting NCT05051657 - Evaluation of the Express Plus Range N/A
Completed NCT02404337 - Betaine METABOLISM OF PATIENTS With Homocystinuria Phase 2
Completed NCT04021732 - Effects of Exercise on Metabolic Parameters in Classical Homocystinuria
Active, not recruiting NCT03406611 - Pegtibatinase as an Enzyme Therapy for Patients With Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE) Phase 1/Phase 2
Completed NCT01192828 - Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine Phase 1/Phase 2
Completed NCT00004356 - Study of Homocysteine Metabolism in Homocystinuria N/A
Recruiting NCT06247085 - A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment Phase 3
Enrolling by invitation NCT06431893 - A Phase 3 Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Phase 3